EMD Stock Overview
Emyria Limited, empresa biotecnológica en fase clínica, se dedica al desarrollo de tratamientos para necesidades médicas no cubiertas.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Emyria Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.064 |
| 52 Week High | AU$0.18 |
| 52 Week Low | AU$0.041 |
| Beta | 0.76 |
| 1 Month Change | -5.88% |
| 3 Month Change | 8.47% |
| 1 Year Change | -63.43% |
| 3 Year Change | -70.91% |
| 5 Year Change | n/a |
| Change since IPO | -55.86% |
Recent News & Updates
Recent updates
Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 02
We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely
May 20Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation
Oct 20We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully
Jun 11Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 25Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares
Nov 17Shareholder Returns
| EMD | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 8.5% | -2.2% | -1.5% |
| 1Y | -63.4% | 45.0% | 8.5% |
Rentabilidad frente al sector: EMD obtuvo unos resultados inferiores a los del sector Australian Pharmaceuticals , que el año pasado arrojó un rendimiento del 60.1%.
Rentabilidad vs. Mercado: EMD obtuvo unos resultados inferiores a los del mercado Australian, que fue del 4.3% el año pasado.
Price Volatility
| EMD volatility | |
|---|---|
| EMD Average Weekly Movement | 16.5% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.3% |
Precio estable de las acciones: El precio de las acciones de EMD ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: EMD(16%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de Australian.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Michael Winlo | https://emyria.com |
Emyria Limited, empresa biotecnológica en fase clínica, se dedica al desarrollo de tratamientos para necesidades médicas no cubiertas. La empresa desarrolla terapias asistidas por psicodélicos, así como un programa de descubrimiento de fármacos con MDMA. Su programa de desarrollo de fármacos incluye EMD-RX5 para el tratamiento de la angustia psicológica y el estrés y la ansiedad leves.
Emyria Limited Fundamentals Summary
| EMD fundamental statistics | |
|---|---|
| Market cap | AU$23.46m |
| Earnings (TTM) | -AU$11.95m |
| Revenue (TTM) | AU$1.95m |
12.0x
P/S Ratio-2.0x
P/E RatioIs EMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMD income statement (TTM) | |
|---|---|
| Revenue | AU$1.95m |
| Cost of Revenue | AU$2.19m |
| Gross Profit | -AU$242.81k |
| Other Expenses | AU$11.71m |
| Earnings | -AU$11.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | -12.45% |
| Net Profit Margin | -612.98% |
| Debt/Equity Ratio | 204.4% |
How did EMD perform over the long term?
See historical performance and comparison